文献速递心力衰竭与心肌病

羧基麦芽糖铁对慢性心力衰竭合并铁缺乏患者运动能力的影响

Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency.
PubMed 文献 · Circulation · 2017-07-12

本研究纳入172例射血分数≤45%且症状轻至中度的心力衰竭合并铁缺乏患者,随机接受静脉羧基麦芽糖铁(FCM)治疗24周或标准治疗。主要终点为峰值耗氧量(peak VO2)变化;FCM组peak VO2维持而对照组下降,组间差异显著(P=0.020),但该效应对死亡患者缺失数据的填补策略高度敏感。

要点

  • FCM显著增加血清铁蛋白和转铁蛋白饱和度。
  • 24周时对照组peak VO2下降,FCM组维持,组间P=0.020。
  • 未填补缺失数据时组间差异不显著(P=0.23)。

核心结论

  • 静脉FCM改善心衰合并铁缺乏患者的铁储备,主要分析中观察到对peak VO2的有利效应,但该效应对死亡患者peak VO2缺失数据的填补策略高度敏感。

研究设计与样本

  • 随机对照试验,172例收缩性心衰(LVEF≤45%)且症状轻至中度、已接受最佳药物治疗的患者,1:1随机接受FCM治疗24周或标准治疗。

主要发现

  • 基线平均年龄64岁,75%为男性,平均LVEF 32%,peak VO2 13.5 mL/min/kg。
  • 24周时对照组peak VO2最小二乘均值下降-1.19±0.389 mL/min/kg,FCM组为-0.16±0.387 mL/min/kg,组间P=0.020。
  • 未填补缺失数据时,对照组peak VO2下降-0.63±0.375 mL/min/kg,FCM组下降-0.16±0.373 mL/min/kg,组间P=0.23。
  • FCM组患者整体评估和NYHA功能分级较标准治疗组改善。

临床怎么用

  • 对收缩性心衰合并铁缺乏患者,可考虑静脉FCM以改善铁储备及功能状态,但peak VO2获益受统计方法影响,需个体化评估。

局限性

  • 主要终点结果对死亡患者peak VO2缺失数据的填补策略高度敏感,需进一步研究FCM是否改善高危患者结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Iron deficiency is common in patients with heart failure (HF) and is associated with reduced exercise capacity and poor outcomes. Whether correction of iron deficiency with (intravenous) ferric carboxymaltose (FCM) affects peak oxygen consumption [peak VO2], an objective measure of exercise intolerance in HF, has not been examined. METHODS: We studied patients with systolic HF (left ventricular ejection fraction ≤45%) and mild to moderate symptoms despite optimal HF medication. Patients were randomized 1:1 to treatment with FCM for 24 weeks or standard of care. The primary end point was the change in peak VO2 from baseline to 24 weeks. Secondary end points included the effect on hematinic and cardiac biomarkers, quality of life, and safety. For the primary analysis, patients who died had a value of 0 imputed for 24-week peak VO2. Additional sensitivity analyses were performed to determine the impact of imputation of missing peak VO2 data. RESULTS: A total of 172 patients with HF were studied and received FCM (n=86) or standard of care (control group, n=86). At baseline, the groups were well matched; mean age was 64 years, 75% were male, mean left ventricular ejection fraction was 32%, and peak VO2 was 13.5 mL/min/kg. FCM significantly increased serum ferritin and transferrin saturation. At 24 weeks, peak VO2 had decreased in the control group (least square means -1.19±0.389 mL/min/kg) but was maintained on FCM (-0.16±0.387 mL/min/kg; P=0.020 between groups). In a sensitivity analysis, in which missing data were not imputed, peak VO2 at 24 weeks decreased by -0.63±0.375 mL/min/kg in the control group and by -0.16±0.373 mL/min/kg in the FCM group; P=0.23 between groups). Patients' global assessment and functional class as assessed by the New York Heart Association improved on FCM versus standard of care. CONCLUSIONS: Treatment with intravenous FCM in patients with HF and iron deficiency improves iron stores. Although a favorable effect on peak VO2 was observed on FCM, compared with standard of care in the primary analysis, this effect was highly sensitive to the imputation strategy for peak VO2 among patients who died. Whether FCM is associated with an improved outcome in these high-risk patients needs further study. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01394562.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. van Veldhuisen DJ, Ponikowski P, van der Meer P, et al. Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency. Circulation. 2017. PMID: 28701470. doi:10.1161/CIRCULATIONAHA.117.027497

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。